Molecular docking simulations were conducted to evaluate the binding affinity of Celecoxib (PUBCHEM_CID: 2662) to CASP9 (PD) and PDK1 (AD, ALS), selected for its multi-target potential, anti-inflammatory properties, and ability to modulate mitochondrial metabolism and apoptosis pathways (Figure 6C and Supplementary Table S11). This evidence concerns the gene PDK1 and Parkinson disease.